Policy | October 12, 2025
AstraZeneca to lower cost of medicines for American patients
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Subscribe To Our Newsletter & Stay Updated
